Get Premium to unlock powerful stock data

Rock Springs Capital Management LP Buys Baxter International Inc, Warby Parker Inc, Ultragenyx Pharmaceutical Inc, Sells BeiGene, Ardelyx Inc, Biogen Inc

Author's Avatar
insider
Nov 16, 2021
Article's Main Image
Baltimore, MD, based Investment company Rock Springs Capital Management LP (Current Portfolio) buys Baxter International Inc, Warby Parker Inc, Ultragenyx Pharmaceutical Inc, Immuneering Corp, Ascendis Pharma A/S, sells BeiGene, Ardelyx Inc, Biogen Inc, Boston Scientific Corp, PPD Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Rock Springs Capital Management LP. As of 2021Q3, Rock Springs Capital Management LP owns 145 stocks with a total value of $4.7 billion. These are the details of the buys and sells.

For the details of Rock Springs Capital Management LP's stock buys and sells, go to https://www.gurufocus.com/guru/rock+springs+capital+management+lp/current-portfolio/portfolio

These are the top 5 holdings of Rock Springs Capital Management LP
  1. Agilon Health Inc (AGL) - 7,075,000 shares, 3.94% of the total portfolio. Shares added by 1.09%
  2. Align Technology Inc (ALGN) - 200,000 shares, 2.83% of the total portfolio. Shares added by 6.52%
  3. Humana Inc (HUM) - 342,000 shares, 2.83% of the total portfolio. Shares added by 13.06%
  4. Insulet Corp (PODD) - 437,566 shares, 2.64% of the total portfolio. Shares added by 7.05%
  5. Intuitive Surgical Inc (ISRG) - 360,000 shares, 2.54% of the total portfolio.
New Purchase: Baxter International Inc (BAX)

Rock Springs Capital Management LP initiated holding in Baxter International Inc. The purchase prices were between $73.77 and $83.61, with an estimated average price of $79.12. The stock is now traded at around $79.650000. The impact to a portfolio due to this purchase was 0.77%. The holding were 450,000 shares as of 2021-09-30.

New Purchase: Warby Parker Inc (WRBY)

Rock Springs Capital Management LP initiated holding in Warby Parker Inc. The purchase prices were between $53.05 and $54.49, with an estimated average price of $53.77. The stock is now traded at around $58.535000. The impact to a portfolio due to this purchase was 0.73%. The holding were 650,000 shares as of 2021-09-30.

New Purchase: Immuneering Corp (IMRX)

Rock Springs Capital Management LP initiated holding in Immuneering Corp. The purchase prices were between $17 and $32.84, with an estimated average price of $26.9. The stock is now traded at around $27.290000. The impact to a portfolio due to this purchase was 0.62%. The holding were 1,089,816 shares as of 2021-09-30.

New Purchase: Acumen Pharmaceuticals Inc (ABOS)

Rock Springs Capital Management LP initiated holding in Acumen Pharmaceuticals Inc. The purchase prices were between $14.5 and $20.28, with an estimated average price of $16.68. The stock is now traded at around $10.735000. The impact to a portfolio due to this purchase was 0.5%. The holding were 1,579,191 shares as of 2021-09-30.

New Purchase: Aadi Bioscience Inc (AADI)

Rock Springs Capital Management LP initiated holding in Aadi Bioscience Inc. The purchase prices were between $0 and $32.66, with an estimated average price of $27.53. The stock is now traded at around $25.450000. The impact to a portfolio due to this purchase was 0.48%. The holding were 764,701 shares as of 2021-09-30.

New Purchase: Icosavax Inc (ICVX)

Rock Springs Capital Management LP initiated holding in Icosavax Inc. The purchase prices were between $24.85 and $40.25, with an estimated average price of $34.02. The stock is now traded at around $26.790000. The impact to a portfolio due to this purchase was 0.46%. The holding were 734,215 shares as of 2021-09-30.

Added: Ultragenyx Pharmaceutical Inc (RARE)

Rock Springs Capital Management LP added to a holding in Ultragenyx Pharmaceutical Inc by 72.28%. The purchase prices were between $77.92 and $102.4, with an estimated average price of $90.63. The stock is now traded at around $79.420000. The impact to a portfolio due to this purchase was 0.65%. The holding were 801,109 shares as of 2021-09-30.

Added: Ascendis Pharma A/S (ASND)

Rock Springs Capital Management LP added to a holding in Ascendis Pharma A/S by 71.31%. The purchase prices were between $112.67 and $176.92, with an estimated average price of $137.27. The stock is now traded at around $154.720000. The impact to a portfolio due to this purchase was 0.57%. The holding were 400,000 shares as of 2021-09-30.

Added: Cerevel Therapeutics Holdings Inc (CERE)

Rock Springs Capital Management LP added to a holding in Cerevel Therapeutics Holdings Inc by 57.39%. The purchase prices were between $21.26 and $38.85, with an estimated average price of $28.11. The stock is now traded at around $37.820000. The impact to a portfolio due to this purchase was 0.36%. The holding were 1,600,589 shares as of 2021-09-30.

Added: Accolade Inc (ACCD)

Rock Springs Capital Management LP added to a holding in Accolade Inc by 38.80%. The purchase prices were between $41.3 and $54.56, with an estimated average price of $47.11. The stock is now traded at around $34.495000. The impact to a portfolio due to this purchase was 0.23%. The holding were 923,000 shares as of 2021-09-30.

Added: Sierra Oncology Inc (SRRA)

Rock Springs Capital Management LP added to a holding in Sierra Oncology Inc by 28.99%. The purchase prices were between $16.4 and $23.1, with an estimated average price of $19.99. The stock is now traded at around $22.410000. The impact to a portfolio due to this purchase was 0.14%. The holding were 1,313,997 shares as of 2021-09-30.

Added: Macrogenics Inc (MGNX)

Rock Springs Capital Management LP added to a holding in Macrogenics Inc by 40.81%. The purchase prices were between $19.74 and $28.7, with an estimated average price of $24.13. The stock is now traded at around $19.205000. The impact to a portfolio due to this purchase was 0.08%. The holding were 641,816 shares as of 2021-09-30.

Sold Out: BeiGene Ltd (BGNE)

Rock Springs Capital Management LP sold out a holding in BeiGene Ltd. The sale prices were between $249.6 and $403.14, with an estimated average price of $327.28.

Sold Out: Ardelyx Inc (ARDX)

Rock Springs Capital Management LP sold out a holding in Ardelyx Inc. The sale prices were between $1.27 and $8.17, with an estimated average price of $2.73.

Sold Out: Biogen Inc (BIIB)

Rock Springs Capital Management LP sold out a holding in Biogen Inc. The sale prices were between $282.99 and $369.05, with an estimated average price of $328.16.

Sold Out: Boston Scientific Corp (BSX)

Rock Springs Capital Management LP sold out a holding in Boston Scientific Corp. The sale prices were between $41.23 and $45.88, with an estimated average price of $44.25.

Sold Out: PPD Inc (PPD)

Rock Springs Capital Management LP sold out a holding in PPD Inc. The sale prices were between $45.75 and $46.85, with an estimated average price of $46.29.

Sold Out: Adaptive Biotechnologies Corp (ADPT)

Rock Springs Capital Management LP sold out a holding in Adaptive Biotechnologies Corp. The sale prices were between $30.02 and $39.87, with an estimated average price of $36.27.



Here is the complete portfolio of Rock Springs Capital Management LP. Also check out:

1. Rock Springs Capital Management LP's Undervalued Stocks
2. Rock Springs Capital Management LP's Top Growth Companies, and
3. Rock Springs Capital Management LP's High Yield stocks
4. Stocks that Rock Springs Capital Management LP keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus